https://orcid.org/0000-0003-1217-4385
References
- Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847. doi: 10.1056/NEJMoa1609783
- Luger S, Mattison R, Paietta E, et al. Assessment of outcomes of consolidation therapy by number of cycles of Blinatumomab received in newly diagnosed measurable residual disease negative patients with B-Lineage acute lymphoblastic leukemia: In the ECOG-ACRIN E1910 randomized phase III national clinical trials network trial. ASH. 2023:Abstract 2877. Available from: https://ash.confex.com/ash/2023/webprogram/Paper189648.html
- Chiaretti S, Santoro A, Spinelli O, et al. Sequential chemotherapy and Blinatumomab to improve minimal residual disease in adult Ph- B-Lineage acute lymphoblastic leukemia. Final results of the phase II Gimema LAL2317 Trial. ASH. 2023;142(Supplement 1):826–826. Available from: https://ash.confex.com/ash/2023/webprogram/Paper174973.html
- Lu J, Qiu H, Lu X, et al. Reduced-dose chemotherapy followed by Blinatumomab as induction therapy in treatment of newly diagnosed Philadelphia chromosome-negative B-Cell precursor acute lymphoblastic leukemia - interim results from a multicenter, single-arm, phase 2 study. ASH. 2023;142(Supplement 1):4243–4243. Available from: https://ash.confex.com/ash/2023/webprogram/Paper174831.html
- Goekbuget N, Faul C, Subklewe M, et al. Dose reduced chemotherapy in sequence with Blinatumomab for newly diagnosed older patients with Ph/BCR: ABL negative B-Precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL bold trial. ASH. 2023;142(Supplement 1):964–964. Available from: https://ash.confex.com/ash/2023/webprogram/Paper180472.html
- Haddad F, Jain N, Short N, et al. Chemotherapy-free combination of Blinatumomab and Ponatinib in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia: updates from a phase II trial. ASH. 2023;142(Supplement 1):2827–2827. Available from: https://ash.confex.com/ash/2023/webprogram/Paper188064.html
- Nguyen D, Short N, Jain N, et al. Updated results from a phase II study of hyper-CVAD, with or without Inotuzumab Ozogamicin, and sequential blinatumomab in patients with newly diagnosed B-Cell acute lymphoblastic leukemia. ASH. 2023:Abstract 2425. Available from: https://ash.confex.com/ash/2023/webprogram/Paper190902.html
- Jen W, Jabbour E, Haddad F, et al. A phase II study of low-intensity chemotherapy (mini-hyper-CVD) and ponatinib followed by Blinatumomab and ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. ASH. 2023;142(Supplement 1):2868–2868. Available from: https://ash.confex.com/ash/2023/webprogram/Paper182997.html
- Webster J, Rimando J, Zeidan A, et al. Blinatumomab in combination with immune checkpoint inhibitors (ICIs) of PD-1 and CTLA-4 in adult patients with relapsed/refractory (R/R) CD19 positive B-Cell acute lymphoblastic leukemia (ALL): results of a phase I study. ASH. 2023;142(Supplement 1):966–966. Available from: https://ash.confex.com/ash/2023/webprogram/Paper191109.html
- Murthy G, Duvall A, Leonard J, et al. A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with relapsed/refractory T-Cell acute lymphoblastic leukemia. ASH. 2023;142(Supplement 1):4242–4242. Available from: https://ash.confex.com/ash/2023/webprogram/Paper187468.html
- Murthy G, Badar T, Yi C, et al. A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia. ASH. 2023;142(Supplement 1):1541–1541. Available from: https://ash.confex.com/ash/2023/webprogram/Paper187721.html
- Nguyen D, Wang S, Jorgensen J, et al. A phase II study of vibecotamab, a CD3-CD123 bispecific T-Cell engaging antibody, for MDS or CMML after hypomethylating failure and in MRD-Positive AML. ASH. 2023;142(Supplement 1):322–322. Available from: https://ash.confex.com/ash/2023/webprogram/Paper190693.html
- Hutchings M, Santoro A, Hou H, et al. Dose escalation of HLA-A2-WT1 CD3 T-Cell bispecific antibody in a phase I study in patients with relapsed/refractory acute myeloid leukemia (AML). Blood. 2023;142(Supplement 1):1537–1537. Available from: https://ash.confex.com/ash/2023/webprogram/Paper173302.html